机构:[1]Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China[2]TheGeneral Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing 100053,China[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China首都医科大学附属天坛医院[4]Department ofNeurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China神经科系统神经外科首都医科大学宣武医院
A nationwide survey was conducted from October 2018 to September 2019 to assess the prevalence of hyperhomocysteinemia (Hhcy) and its influencing factors in China. A standardized questionnaire was used to collect information. Hhcy was defined as the level of serum homocysteine (HCY) > 15.0 mu mol/L. The H-type hypertension (HHYP) was defined as hypertension with an elevated serum HCY 15.0 mu mol/L). Finally, 110 551 residents > 40 years of age from 31 provinces in the mainland of China were included. Overall, the median serum HCY level was 10.9 mu mol/L (interquartile range 7.9-15.1). A total of 28 633 participants (25.9%) were defined as Hhcy. The Hhcy prevalence ranged from 7.9% in Shanghai to 56.8% in Tianjin. The data showed that serum HCY levels were associated with age, male gender, cigarette smoking, hypertension, diabetes, ethnicity, endurance in exercise (inverse), and fruit and vegetable intake (inverse). In addition, 15 486 participants were defined as HHYP, and the rate was 14.0%. HHYP was an independent predictor of stroke with an adjusted odds ratio of 1.752 (95% CI 1.338-2.105). The geographical distribution pattern of the Hhcy epidemic reflects dynamic differences, and national strategies should be carried out to further improve the care of patients with Hhcy across China.
基金:
Special Plan of the Ministry of Science and Technology of the People's Republic of China [Z135080000022]; CAMS Innovation Fund for Medical Science [2017-I2M-1-016, 2019-I2M-2-006]; Natural Science Foundation of TianjinNatural Science Foundation of Tianjin [19JCYBJC26600]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M660921, 2020T130436]; Science Foundation for Post Doctorate Research of the Beijing [2017-ZZ-123, 2020-ZZ-005]
第一作者机构:[1]Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China[2]TheGeneral Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing 100053,China[3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Tu Wenjun,Yan Feng,Chao Baohua,et al.Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018[J].FRONTIERS OF MEDICINE.2021,15(6):903-912.doi:10.1007/s11684-021-0871-4.
APA:
Tu, Wenjun,Yan, Feng,Chao, Baohua,Ji, Xunming&Wang, Longde.(2021).Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018.FRONTIERS OF MEDICINE,15,(6)
MLA:
Tu, Wenjun,et al."Status of hyperhomocysteinemia in China: results from the China Stroke High-risk Population Screening Program, 2018".FRONTIERS OF MEDICINE 15..6(2021):903-912